EMEA-001656-PIP02-19

Key facts

Active substance
Momelotinib
Therapeutic area
Oncology
Decision number
P/0249/2019
PIP number
EMEA-001656-PIP02-19
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of myelofibrosis
Route(s) of administration
Oral use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited

Tel. +1 438-899-8201
E-mail: eu.paediatric-plans@gsk.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating
Average
1 rating